Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379894 | 0.91 | ALDH1A1 (0.74) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL1337891 | 0.91 | ALDH1A1 (0.74) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL497006 | 0.90 | MAPK1 (0.73) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL3912077 | 0.86 | L3MBTL1 (0.62) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL21463826 | 0.84 | ALDH1A1 (0.60) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL4606261 | 0.83 | MAPK1 (0.55) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL11506844 | 0.83 | ALDH1A1 (0.89) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL6656393 | 0.82 | MAPK1 (0.62) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL3913669 | 0.81 | MAPK1 (0.68) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 | |
| SCHEMBL30310075 | 0.81 | MAPK1 (0.68) | ALDH1A1MAPK1TDP1L3MBTL1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974779-B2 | Piperidine derivatives as human papilloma virus inhibitors | VAXART, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | VAXART, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | AVIRAGEN THERAPEUTICS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9452991-B2 | Piperidine derivatives as human papilloma virus inhibitors | AVIRAGEN THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| EP-2024350-B1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA (FR) | 2013-09-18 | — | — | EP | disclosed |
| CN-101466693-B | Piperidine derivatives as human papilloma virus inhibitors | ANACONDA PHARMA | 2012-12-12 | — | — | CN | disclosed |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2012-08-30 | — | — | US | disclosed |
| US-8207373-B2 | Benzoic acid derivatives as human papilloma virus inhibitors | ANACONDA PHARMA (FR) | 2012-06-26 | — | — | US | disclosed |
| US-20090209586-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2009-08-20 | — | — | US | disclosed |
| EP-2024350-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | Anaconda Pharma (FR) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135106-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | ALDH1A1 452/4885MAPK1 3238/4885TDP1 1151/4885 |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | ALDH1A1 784/4885MAPK1 3007/4885TDP1 3969/4885 |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | ALDH1A1 452/4885MAPK1 3238/4885TDP1 1151/4885 |
| US-20090209586-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, IDH1, CBR3 | ALDH1A1 123/4885MAPK1 2074/4885TDP1 2991/4885 |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, CBR3, CBR1 | ALDH1A1 138/4885MAPK1 2332/4885TDP1 2966/4885 |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | ALDH1A1 784/4885MAPK1 3007/4885TDP1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.